How to appeal a CareFirst BCBS atopic dermatitis (ad / eczema) denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

CareFirst BCBS-specific note: BCBS licensee for Maryland, DC, and northern Virginia (~3.5M members). Operates as non-profit. Appeals jurisdiction depends on policy issue location — MIA (MD), DISB (DC), or SCC Bureau of Insurance (VA). CVS Caremark is the PBM.

What CareFirst BCBS's policy requires for atopic dermatitis (ad / eczema)

Cited policy: BCBS Ebglyss (Lebrikizumab) for AD PA

Age >=12 yr and >=40 kg per Sep 2024 label. Moderate-severe AD. Failure of topical therapy. Step-therapy through Dupixent typical; contraindication or AE accepted. Reauth 16 wk EASI-75 or IGA 0/1.

How CareFirst BCBS denies atopic dermatitis (ad / eczema) — and how to counter it

Where CareFirst BCBS pushes back: 1) Try Dupixent or Adbry first; 2) Insufficient evidence vs older biologics.

Counter-arguments that hold up: Ebglyss IL-13 high-affinity binding (distinct epitope from Adbry / Dupixent IL-4Rα). FDA Sep 13, 2024 ages 12+ supported by ADvocate-1 + ADvocate-2 (Silverberg NEJM 2023 — EASI-75 ~58% vs ~16% placebo at 16 wk monotherapy), ADhere (with TCS), ADore (12-17). AAD 2024 + ETFAD/EADV 2024 list IL-13 selective biologics as parallel options. Class switching after Dupixent AE (conjunctivitis, facial dermatitis) or partial response is rational.

What CareFirst BCBS typically denies for atopic dermatitis (ad / eczema)

Across CareFirst BCBS's commercial and Medicare books, denials cluster around a small number of patterns. For atopic dermatitis (ad / eczema), expect:

• DC/MD/VA cross-jurisdiction issues
• Step therapy on specialty drugs via CVS Caremark
• Behavioral health network adequacy
• BlueChoice HMO referral denials

Treatments most often denied in this category

These are the atopic dermatitis (ad / eczema) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Dupixent (AD)
• Adbry
• Ebglyss
• Nemluvio (AD)
• Cibinqo
• Rinvoq (AD)

How to submit the appeal to CareFirst BCBS

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document CareFirst BCBS cited in the denial.
3. File the appeal through CareFirst BCBS's portal (members: https://member.carefirst.com ; providers: https://provider.carefirst.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MD, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See CareFirst BCBS's prior-authorization criteria by drug: CareFirst BCBS PA criteria on ApprovalHelp.